Clinical trials: Reduced Vision
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Retinitis Pigmentosa, Retinitis
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- RESTORE (NCT04945772)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Nanoscope Therapeutics Inc.
Macular Edema
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
- Trial name
- DRAKO (NCT02850263)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Bayer
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.
- Trial name
- NCT00825396
- Testing
- C-KAD Ophthalmic Solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Chakshu Research, Inc.
Diabetic Macula Edema
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- BUZZARD (NCT04079231)
- Testing
- Brolucizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Allergic Conjunctivitis
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC…
- Trial name
- NCT05265910
- Testing
- olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Andover Research Eye Institute
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Visual Impairment
Measuring of Neuro-visual Functionality With Ocusweep
The aim of this study is to measure visual acuity, contrast sensitivity and visual field by SAP-method using a novel device Ocusweep compared to currently widely used methods.
- Trial name
- NCT02258113
- Testing
- Ocusweep, Ocusweep OcuRT
- Where
- Finland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Ocuspecto Oy
Nonalcoholic Steatohepatitis
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia VERJU and EVRL laser devices is effective in reducing aminoalanine transaminase (ALT) levels in individuals with nonalcoholic…
- Trial name
- NCT03163810
- Testing
- Erchonia Verju Laser, Erchonia EVRL Laser
- Where
- United States
- Sponsor
- Erchonia Corporation
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Visual Impairment, Macular Edema
A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.
- Trial name
- LUDIC (NCT01315275)
- Testing
- Ranibizumab
- Where
- 43 sites in France
- Volunteers
- 394 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 9 sites in United States
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Primary Open Angle Glaucoma (POAG)
One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the intraocular pressure (IOP) lowering effect of one, two, or three iStent devices in eyes of subjects previously on two anti-glaucoma medications.
- Trial name
- NCT01517477
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Macular Edema, Macular Degeneration
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
The study was designed to assess the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting with reduced visual acuity due to diabetic macular edema and evaluating spacing out of follow-up after…
- Conditions
- Macular Edema, Macular Degeneration, Diabetes
- Trial name
- CONSTELLATION (NCT02032173)
- Testing
- Ranibizumab 0.5mg
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLIMMER (NCT04603937)
- Testing
- KSI-301, Aflibercept
- Where
- 72 sites in United States, Czechia and 6 more
- Volunteers
- 459 people
- Sponsor
- Kodiak Sciences Inc
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals